Genentech warns of Avastin and Sutent combo in kidney cancer - update
This article was originally published in Scrip
Executive Summary
Genentechhas warned physicians about several cases of microangiopathic hemolytic anaemia (MAHA) seen in patients treated with its anticancer Avastin (bevacizumab) in combination with Pfizer’s Sutent (sunitinib maleate) in an early trial of metastatic kidney cancer, according to the FDA. The reaction is reversible, and has so far been seen with high doses of Sutent.